The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 of 18 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 123Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 65Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 119Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 66Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 98Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 117Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 60Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 86Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 70Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 126Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,101–1,200 of 1,251
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Morgan, G. J., Lee, D. D., Joseph, N. S., Lonial, S., Rodríguez‐Otero, P., & San-Miguel, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517494
Self-citationTherapeutic effect of T-cell engager in two patients with autoimmune neuropathy
Wickel, J., Ceangă, M., Vlad, B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73819-1
“Here, we applied teclistamab, a BiTE approved for the treatment of relapsed or refractory multiple myeloma 10 , as a fi rst-in-class treat-ment for neuroimmunological diseases.”
Rousseau, M., Deweweire, A., Depaus, J., & Claes, G. (2026) · Cureus · doi:10.7759/cureus.109924
Multiples Myelom: Management von immunvermittelten Nebenwirkungen von Immuntherapien
Högner, M. (2026) · Trillium Krebsmedizin · doi:10.47184/tk.2026.03.5
Antibody–drug conjugates in hematologic malignancies
Patel, K., Strickland, S. A., & Lee, H. C. (2026) · Cancer · doi:10.1002/cncr.70421
From T cell engagers to next-generation immune cell engagers for cancer immunotherapy
Yang, Z., & Fu, Y. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag030
A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma
Li, R., Huang, L., Hao, Z., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-05344-y
“Teclistamab targets BCMA and CD3 and has shown activity in relapsed/refractory MM [26], while elranatamab, another BCMA–CD3 bispecific antibody, demonstrated clinically meaningful activity in the phase 2 MagnetisMM-3 trial [50].”
Hansen, D. K., Mateos, M., & Costa, L. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019699
“51 52-57 Emerging data indicate many patients responding to TCE may be able to discontinue therapy without compromising with disease control.”
Self-citationEngineering a TACI × CD3 bispecific antibody to redirect T cells against multiple myeloma
Zhang, M., Leong, W. F., Huo, J., Ngoh, E. Z. X., Loh, H. P., Chen, Q., Toh, S. H. M., Mel, S. D., Ooi, M. G. M., Soekojo, C. Y., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018210
“15,16 Notably, ciltacabtagene autoleucel and idecabtagene vicleucel were approved in 2021 and 2022, respectively, and teclistamab, a BCMA-targeted T-cell–redirecting bsAb, received accelerated approval in 2022.”
Lipof, J. J., Bloudek, B., Ray, A., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.014
Self-citationIrfan, S., Jamil, M. A., & Abid, M. B. (2026) · British Journal of Haematology · doi:10.1111/bjh.70607
Multi-objective antibody design and optimization using machine learning
Kuo, Y., Brown, C. N., Akin, E., Xie, Y., & Tessier, P. M. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00444-4
Montefusco, V., Cafro, A. M., Margiotta‐Casaluci, G., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.013
Song, Y., Zhou, X., & Wang, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1859755
Bertuglia, G., Nicola, A. D., Gay, F., Larocca, A., Bruno, B., & D’Agostino, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822419
Patel, K. K., Hasegawa, K., Ting, J., Sidana, S., Zoratti, M. J., Wennersbusch, D., Kanters, S., Kostic, A., Itani, T., & Hansen, D. K. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2688385
Self-citationShah, M. R., Bag, A., Shrestha, A., Ogunsesan, Y., Trikannad, A., Vellanki, S., Muttineni, S., Cheema, H., Naqvi, S., Dronavalli, S., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9451393/v1
Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma
Biltibo, E. A., Chakraborty, R., & Bishop, M. R. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517460
Tang, B., Kim, G., Chen, T., & Tam, H. L. A. E. L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016149
Henaff, J.-R. L., Guennec, L. L., Schirò, P., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020556
Liang, T., Li, J., & Xu, C. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00967-3
Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis
Nakaa, S., Caillot, L., Chermak, A., Kemp, H., Harel, S., Darmon, M., Azoulay, É., & Lemiale, V. (2026) · Annals of Intensive Care · doi:10.1016/j.aicoj.2026.100100
“Even for patient with relapsed or refractory MM, these advances lead to an extended survival, with high level of quality of life [2 – 6].”
Cazaubiel, T., Touzeau, C., Vincent, L., Belhadj, K., Karlin, L., Manier, S., Perrot, A., Vekemans, M. C., Moyer, P., Moreau, P., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.005
Self-citationGastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status
Domínguez, T. A., Andrés, M. C., Malpartida, K. G., Medina, J. G., Muñoz, M. J. S., Jiménez, W. M. T., Jordan, B. L. D., & Romero, F. B. (2026) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2026.501777
Adrados, A., Pérez‐Fernández, J., García-Vicente, R., Garrote-de-Barros, A., Martínez‐López, J., Linares, M., & Hernández‐Sánchez, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805129
Self-citationPractical Management of Bispecific Antibodies in Multiple Myeloma
Tan, C. R. C., Korde, N., & Mian, H. S. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00159
Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions
Wang, G., Gao, H., Xie, T., & Zi, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116996
Bispecific CAR T and CAR NK cells in dual-threat immunotherapy: opportunities and challenges
Baher, A. S., Khalid, A., Hakemi, A. G., Ganjalikhani-Hakemi, A., Soltani, M., Saltanatpour, Z., Zamyatnin, A. A., Parodi, A., & Ganjalıkhani-Hakemi, M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12144-8 · Cited by 1
MRD in multiple myeloma: Moving from “minimal” to “measurable”
Cassano, R. C., Banerjee, R. K., Afrough, A., Portuguese, A. J., Thakur, R., Cicero, K. I., Kwok, M., Foster, L. H., Buda, G., Meletath, S. K., et al. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101413
Yanamandra, U., Ramachandran, R., Sakhuja, V., Nair, R. K., Jha, V., Kumar, S. K., Leung, N., & Malhotra, P. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.006
Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments
Ansari, A. M., Attaripour, S., Garg, S., & Tabbara, I. A. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2675661
Fiori, E., Bertschinger, M., Bacher, U., Hoffmann, M., Nilius, H., Seipel, K., & Pabst, T. (2026) · Biomedicines · doi:10.3390/biomedicines14061392
“The most advanced BsAbs in the treatment of RRMM are directed against B-cell maturation antigen (BCMA), elranatamab [6] and teclistamab [7] or against G protein-coupled receptor family C group 5 member D (GPRC5D), such as talquetamab [8].”
Burke, O. J., Peruzzo, N., Khan, N. T. A., & Kancharla, P. (2026) · Cureus · doi:10.7759/cureus.111438
Gao, M.-J., Ouyang, G.-F., Liu, Y.-G., Chen, S.-K., & Xu, K.-H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1856163 · Cited by 1
Mina, R., Terpos, E., Cani, L., Nooka, A. K., Trudel, S., Voorhees, P., Mian, H. S., Dhakal, B., Usmani, S. Z., Richter, J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.014
Self-citationAdvances in the Research of Bispecific Antibodies in Immunotherapy for Multiple Myeloma
利, 浩. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.53213
Roncato, R., Pasin, D., Dell’Aquila, E., Danesi, R., & Re, M. D. (2026) · Chemotherapy · doi:10.1159/000553142
Kidney Transplantation Post–Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma
Khan, Z., Dadhania, D. M., Brailovski, E., Landau, H. J., & Shaikh, A. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.04.012
Bose, C. K. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1824552
Not Always ICANS: Interpreting Neurotoxicity With Tarlatamab in SCLC
Hennawy, M., Harrison, R. A., & Ho, C. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103723
Mestiri, S., Assami, L., Yoosuf, Z. S. K. M., Fernandes, Q., El-Ella, D. M. A., Elsabah, H., Merhi, M., Makni‐Maalej, K., Cherif, H., Dermime, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1822508 · Cited by 1
“Multi-speci fi c immune cell-engaging antibodies such as bi-speci fi c (BsAbs), tri-speci fi c (TsAbs), and tetra-speci fi c antibodies are designed to recognize two or more antigens on the same or distinct cells (9).”
Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma
Worth, H. A., & Costa, L. J. (2026) · Cancer · doi:10.1002/cncr.70519
Li, T. R., Tredennick, A. T., Polhamus, D. G., Putnins, M., Liu, S., Sanghavi, K., Thalhauser, C. J., Parikh, A., Noorani, B., Mohamed, M. F., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70362
Podvin, B., Lee, H., Tilmont, R., Decool, G., Cavalieri, D., Demarquette, H., Gower, N., Nudel, M., Bourgeois, E., Robu, D., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020518
Self-citationElranatamab: A novel B-cell maturation T-cell engager
Hossain, S., & Bianchi, G. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2694852
“27 Elranatamab had an incidence of 57.7% with no grade 3 or higher events.”
InfluentialBelantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma
Samuel, M., Flores, M. S., Lowy, J. A., Rogers, M. F., Avigan, Z. M., Rattu, M. A., & Richter, J. R. (2026) · Future Oncology · doi:10.1080/14796694.2026.2700028 · Cited by 1
Dual-targeting bispecific antibodies against extramedullary myeloma: A hypothesis-driven commentary
Zhou, S., & Ke, Q.-H. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102907
“Single-antigen targeting exerts selective pressure leading to outgrowth of antigen-low or antigen-negative subclones – well documented with BCMA-directed therapies [4 – 6].”
Merz, M., & Goldschmidt, H. (2026) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_471-2
Ellayan, D. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag203
Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma
Sra, M. S., & Kumar, S. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2703858
“Teclistamab, a humanized IgG4 bispecific characterized by a controlled Fab-arm exchange, became the first BCMA × CD3 bispecific to receive FDA approval in October 2022 on the basis of the phase 1/2 MajesTEC-1 trial [35,36].”
Chen, Y., Tan, Y., Zhang, W., Liu, J., Wang, Q., Tian, T., Yao, H., & Yu, Y. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03204-2
Rethinking On‐Target Off‐Tumor Toxicity as a Hematopoietic Continuum
Morabito, F., Martino, E. A., Bruzzese, A., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70266
“…of continuous immunotherapy exposure with BsAbs has introduced new forms of cumulative immune dysregulation characterized by chronic hypogammaglobu-linemia, recurrent infections, prolonged cytopenias, and progressive T-cell dysfunction associated with sustained antigen engagement [6, 7, 16, 17].”
Herzberg, F., Lu, F., Korenkov, M., Fregona, V., Didoss, C., Heisterkamp, N., Sprechert, M., Polici, A., Heck, C., Haas, S. F., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03047-5
“Bispeci fi c T cell engagers (TCE) targeting B cell maturation antigen (BCMA) or G-protein coupled receptor family C group member D (GPRC5D) have reshaped treatment for relapsed or refractory MM, inducing deep and durable remissions in a subset of patients [3 – 5].”
Muddasani, A., Thanendrarajan, S., Zangari, M., van Rhee, F., & Schinke, C. (2026) · Cancers · doi:10.3390/cancers18142311
“The number of prior therapy lines was proxied using platform-derived VA Class codes for chemotherapy lines 3, 4, and 5.”
BADELITA, S. N., MURARIU, D. N., Mohorea-Neata, A.-L., Barbu, S., Zidaru, L. E., CIRLAN, L., & Coriu, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1844776
Alqazaqi, R., Taasan, S. M., Schwartzman, W. S., Khan, A. M., Afrough, A., Zahid, M. F., Schinke, C., van Rhee, F., Anderson, L. D., Sanchorawala, V., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020740
Tancherla, A., Dharmaraja, F., & Kurniawan, A. (2026) · Oncology Research and Treatment · doi:10.1159/000553500
Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer
Kong, X., Su, Y., Zheng, H., Feng, Z., Huang, J., Zhang, L., & Li, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1895434
When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era
Afrough, A., Dillard, C. M., Alsup, A., Lee, J. H., Hadidi, S. A., Sannareddy, A., Abraham, P. R., Turer, L., Dima, D., Khan, A. M., et al. (2026) · Cancers · doi:10.3390/cancers18152415
“In this trial, 17% ( n = 28) of patients met this criterion, and these patients demonstrated a lower ORR of approximately 35%, compared to 63.0% in the overall population [70].”
InfluentialZerbit, J., Vignon, M., Fouquet, G., Detroit, M., Choquet, S., Garderet, L., Hermine, O., Cazelles, C., Frenzel, L., Mohty, M., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.07.017
Self-citationJurgens, E. M., Mitra, S., Herrera, K., Nemirovsky, D., Bready, B., Derkach, A., Hosszu, K., McAvoy, D. P., Firestone, R., Rajeeve, S., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aed0039 · Cited by 2
Self-citationPierer, M., & Simón, D. (2026) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-026-01846-w
Cai, Z., Xia, Z., He, A., Dong, Y., Wang, Y., Liao, A., Song, Y., Chen, H., Zuppa, A., Chastain, K. M., et al. (2026) · eJHaem · doi:10.1002/jha2.70340
CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease
Groß, N., Jochimsen, A., Dräger, S., Theocharis, T., Recke, A., van Beek, N., Schmidt‐Jiménez, L. F., Krohn, S., Klausz, K., Bieber, K., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201825
Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies
Mina, R., Doyle, M., & Nooka, A. K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03715-z
Self-citationShivarov, V. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30050-9.00021-7
Qi, J., Park, D., Shah, P., & Akhtari, M. (2026) · Hematology Reports · doi:10.3390/hematolrep18040054
“Teclistamab is a bispecific antibody targeting both CD3 on T cells and BCMA on myeloma cells, resulting in T-cell-mediated cytotoxicity of BCMA-expressing myeloma cells [7–9].”
InfluentialAn Overview on T-Cell Engagers: The Current Position in Both the Biological and Mathematical Context
Davies, J., Brown, L., Jones, M. W., Penny, M., & Powathil, G. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0209
“It is important to note that 119 of these patients suffered from some grade of CRS [ 36 ].”
Akrawi, D., Datta, S., Hatipoğlu, S., Wechalekar, A. D., Ghose, A., Alkhateeb, A., Walker, J. M., & Ghosh, A. K. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02397-x
Niazi, S. K. (2026) · Oncology Reviews · doi:10.3389/or.2026.1804447
Patel, K., Boccia, R., Olson, N., Nadkarni, R., Naidu, D., Kodali, A., Clinton, N., Lozano, R., Anandpura, N., Naidu, S., et al. (2026) · NCODA Oncology and Hematology Meeting Abstracts · doi:10.67209/hbqi1345
CAR-T cell therapy for autoimmune diseases: from immune suppression to immune resetting
Zhang, M., Zhao, L., Chen, T., Ding, L., He, L., & Guo, Z. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117231
Cavo, M., Bersanelli, M., Corso, A., Galeone, C., Mangiacavalli, S., Mina, R., Zambello, R., Antonioli, E., Belotti, A., Botta, C., et al. (2026) · Cancers · doi:10.3390/cancers18162572
Besemer, B., & Schenk, A. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2807-6023
Self-citationTai, D., Sandhu, N., Dermarderosian, A., Mkrtchyan, N., Park, D., Garg, V., Nguyen, A., & Akhtari, M. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030060
Shambhavi, S., Singh, H., Amonica, T., Grover, A., Singh, T., Paul, S., Paul, S. S., & Pompa, T. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167179
“…antigens such as BCMA (Teclistamab; Elranatamab), GPRC5D (Talquetamab), and FcRH5 (Cevostamab), bispecific antibodies (BsAbs) or T-cell redirecting therapies have rapidly grown into a novel option for RRMM. Clinical trials have shown substantial activity even in post-BCMA exposed settings [12–15].”
Fogel, L., Parmar, H. V., Wan, S., Phull, P. M., Doucette, K. R., Aleman, A., Anand, P., Franz, J., Vesole, D. H., Siegel, D. S. D., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2714341
Brooks, C., Mader, L., Kennedy, K., Naing, P. T., Sengsayadeth, S. M., Dholaria, B., Kassim, A., Profitt, S., & Baljević, M. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00816-x
“While a majority of pts experienced CRS in the registrational MajesTEC-1 and MonumenTAL-1 studies (72% and 80%, respectively), CRS was typically low-grade and predictable in onset with nearly all events occurring during SUD [3, 4].”
Aparicio‐Minguijón, E., López‐Muñoz, N., Herguedas, G. B., Marín, A. J. S., Asín, M. A. P., Sánchez‐Pina, J. M., Calbacho, M., Boán, J., López‐Medrano, F., Juan, R. S., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag505 · Cited by 1
Self-citationElranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye
Bozdemir, A., Hacıoğlu, S., Çağlıyan, G. A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166232
How to treat hepatic extra-medullary involvement of myeloma: a case report and review of literature
VURAL, E. T., Aytekin, H., Durak, E., Öcal, R., Nevruz, O., Kuzu, I., Gül, S. Ş., & Beksaç, M. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2715203
Tedeschi, A., Pasini, N., Talassi, M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166371
“Although 72.1% of the 165 treated patients developed CRS-related symptoms, vasopressor support was required in only one patient, indicating a comparatively limited CV impact in terms of severe hypotensive events [40].”
InfluentialLi, S., Huang, J., Fang, R., Zhang, M., Jin, Y., Zhu, Y., & Ma, C. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152541
Venglár, O., Radova, E., Warmuzová, M., Bilek, D., Kudelkova, M., Jasinkova, K., Muroňová, L., Broskevičová, L., Kapustová, V., Vrána, J., et al. (2026) · HemaSphere · doi:10.1002/hem3.70455
Thomas, J., Xu, G., Lock, H., Song, Q., Yin, Y., Luo, W., Hong, K., Lou, L., Wang, C., Chinn, L., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2718587
“12,16,25 This broader expression pattern has only recently been appreciated, with the first evidence of a BCMA TCE facilitating depletion of CD19 + B cells in clinical practice reported at the end of 2023.”
InfluentialMultiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 3
Huang, Z.-Y., Wu, W., Luo, G., Huang, H., & Liu, X.-L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848518
Zhai, X., Rong, Z., Lixia, F., Gu, Y., Dong, B., Yao, D., Pang, X., & Cui, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1884087
Nikolaou, V. A., Koumaki, D., Perrot, A., Kastritis, E., Beylot-Barry, M., & Sibaud, V. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.08.010
Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025
Zhang, T., Wang, S., Li, X., Li, X., & Wu, Y. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2711554
Alvaro, M. E., Martino, E. A., Caserta, S., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Morabito, F., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1934257
Drug Resistance in Multiple Myeloma: Tumor‐Intrinsic Mechanisms and the Bone Marrow Microenvironment
Chen, Y., Huang, W., Tang, M., & Wang, X. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70286
Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse
Xie, H., Luo, R., & Zeng, D. (2026) · Archives of Medical Science · doi:10.5114/aoms/230992
Shah, M. R., Bag, A., Shrestha, A., Ogunsesan, Y., Trikannad, A., Vellanki, S., Muttineni, S., Cheema, H., Naqvi, S., Dronavalli, S., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01613-9
Duminuco, A., Palumbo, G. A., Avella, E., Cupri, A., Garibaldi, B., Limoli, M. C., Mauro, E., Patti, S., Risata, N., Romano, S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176520 · Cited by 1
“BCMA-, GPRC5D-, and FcRH5-directed bispecific antibodies (teclistamab, elranatamab, talquetamab, cevostamab) further displace allografting [221,222].”
Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma
Bhatt, M., Rajkumar, S. V., & Kumar, S. K. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70301
Hung, Y.-C., Cho, S., Chen, Y.-Y., Hsu, Y., Huang, S., Wei, C., Tsai, C., Huang, W., & Liu, C. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.08.029
Beyond maximum grade: key regulatory considerations in adverse event reporting
Tzogani, K., El‐Galaly, T. C., Everest, N., Gisselbrecht, C., Mitsuiki, N., Nagai, S., Thompson, R., & Thanarajasingam, G. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00168-7
Artzenroth, J., Kosch, R., Al-Bazaz, M., Bartke, L., Cords, L., Güsmer, C., Harzer, M., Heinrich, F., Kamili, A., Leypoldt, L., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.08.044
EXABS-201-MM: Bispecific Antibodies Should Be Used First for Relapsed/Refractory MM
Usmani, S. Z. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00329-0
Self-citation
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
